Resource Summary Report

Generated by FDI Lab - SciCrunch.org on May 7, 2025

Symmetric Di-Methyl Arginine Motif [sdme-RG] MultiMab Rabbit mAb mix

RRID:AB_2714013
Type: Antibody

Proper Citation

(Cell Signaling Technology Cat# 13222, RRID:AB_2714013)

Antibody Information

URL: http://antibodyregistry.org/AB_2714013

Proper Citation: (Cell Signaling Technology Cat# 13222, RRID:AB_2714013)

Target Antigen: Symmetric Di-Methyl Arginine Motif

Host Organism: rabbit

Clonality: unknown

Comments: Applications: W

Antibody Name: Symmetric Di-Methyl Arginine Motif [sdme-RG] MultiMab Rabbit mAb mix

Description: This unknown targets Symmetric Di-Methyl Arginine Motif

Target Organism: monkey, rat, mouse, human

Antibody ID: AB_2714013

Vendor: Cell Signaling Technology

Catalog Number: 13222

Alternative Catalog Numbers: 13222S

Record Creation Time: 20231110T033813+0000

Record Last Update: 20240725T093613+0000

Ratings and Alerts

No rating or validation information has been found for Symmetric Di-Methyl Arginine Motif [sdme-RG] MultiMab Rabbit mAb mix.

No alerts have been found for Symmetric Di-Methyl Arginine Motif [sdme-RG] MultiMab Rabbit mAb mix.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Verbeke S, et al. (2023) Antitumor Effects of PRMT5 Inhibition in Sarcomas. Cancer research communications, 3(11), 2211.

Li Y, et al. (2023) PRMT blockade induces defective DNA replication stress response and synergizes with PARP inhibition. Cell reports. Medicine, 4(12), 101326.

Engstrom LD, et al. (2023) MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer. Cancer discovery, 13(11), 2412.

Gjuka D, et al. (2023) Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistance. Cancer cell, 41(10), 1774.

Sun Y, et al. (2023) MST2 methylation by PRMT5 inhibits Hippo signaling and promotes pancreatic cancer progression. The EMBO journal, 42(23), e114558.

Maron MI, et al. (2022) Type I and II PRMTs inversely regulate post-transcriptional intron detention through Sm and CHTOP methylation. eLife, 11.

Lu SX, et al. (2021) Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. Cell, 184(15), 4032.

Mulvaney KM, et al. (2021) Molecular basis for substrate recruitment to the PRMT5 methylosome. Molecular cell, 81(17), 3481.

Maron MI, et al. (2021) Independent transcriptomic and proteomic regulation by type I and II protein arginine methyltransferases. iScience, 24(9), 102971.

Kalev P, et al. (2021) MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage. Cancer cell, 39(2), 209.

Metz PJ, et al. (2020) Symmetric Arginine Dimethylation Is Selectively Required for mRNA Splicing and the Initiation of Type I and Type III Interferon Signaling. Cell reports, 30(6), 1935.

Fedoriw A, et al. (2019) Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss. Cancer cell, 36(1), 100.

vanLieshout TL, et al. (2019) Protein arginine methyltransferase biology in humans during acute and chronic skeletal muscle plasticity. Journal of applied physiology (Bethesda, Md. : 1985), 127(3), 867.

Fong JY, et al. (2019) Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation. Cancer cell, 36(2), 194.

Braun CJ, et al. (2017) Coordinated Splicing of Regulatory Detained Introns within Oncogenic Transcripts Creates an Exploitable Vulnerability in Malignant Glioma. Cancer cell, 32(4), 411.